Leonard M. Greenstein - Feb 16, 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Financial Officer
Signature: /s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol: TARS
Transactions as of: Feb 16, 2023
Transactions value $: -$75,600
Form type: 4
Date filed: 2/17/2023, 03:58 PM
Previous filing: Jan 20, 2023
Next filing: Mar 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Sale	-$75.6K	-5K	-12.73%	$15.12	34.3K	Feb 16, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
F2	The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.01 to $15.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.

The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.01 to $15.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.